✓ CME Credit

✓ Poster Sessions

✓ Symposia

---

**Conference Organizers**


**Dr. Donald Ford**
Council for Tobacco Research
900 Third Avenue
4th Floor
New York, New York 10022
(212) 421-8885

**Dr. Fleur L. Strand**
New York University
Department of Biology
Washington Square
100 Washington Square East
Room 1009 Main Building
New York, New York 10003
(212) 998-8282
(212) 998-8283
(212) 995-4015 Fax


**August 9 - August 13 1992**




# Summer NeuroPeptide Conference

**North Falmouth, Cape Cod**
**Massachusetts**

*Preliminary Program*

Source: https://www.industrydocuments.ucsf.edu/docs/rgnv0000

*Preliminary Program*

*Join us at the*

# SECOND SUMMER NEUROPEPTIDE CONFERENCE

**North Falmouth, Cape Cod, Massachusetts**
**August 9-13, 1992**

## *Plenary speaker: David de Wied*

*Rudolf Magnus Institute*
*Utrecht, The Netherlands*

## SYMPOSIA

### *Current Perspectives in Receptor Research*

**Chair: R. J. Lukas, Phoenix, Arizona, USA**
**Organizer: Ronald J. Lukas, Barrow Neurological Institute**

ONCOGENIC AND NON-ONCOGENIC ANGIOTENSIN RECEPTORS
Michael R. Hanley, University of California, Davis

EXCITATORY AND INHIBITORY AMINO ACID RECEPTORS
Richard W. Olsen, University of California, Los Angeles School of Medicine

OPIOID RECEPTORS AND FUNCTION
William R. Martin, University of Kentucky College of Medicine

NICOTINIC RECEPTOR SUBTYPES:
TARGETS FOR THYMOPOIETIN AND OTHER PEPTIDES
Ronald J. Lukas, Barrow Neurological Institute

Source: https://www.industrydocuments.ucsf.edu/docs/rgnv0000

## Neurotensin/Neurotensin-Dopamine Interactions.

**Susan Leeman and Duff Davis, Co-Chairs**

HISTORICAL INTRODUCTION
S.E. Leeman, University of Massachusetts Medical School, Boston, MA

NEUROTENSIN GENE STRUCTURE AND REGULATION BY NGF, GLUCOCORTICOIDS, cAMP, AND LITHIUM IN PC12 CELLS
P.R. Dobner, B.P. Bullock, A.S. Tischler*, and E. Kislauskis. University of Massachusetts Medical Center. * Tufts University School of Medicine, Boston, MA

NEUROTENSIN NEURONS AND THE REGULATION OF GONADOTROPIN-RELEASING HORMONE SECRETION
M.J. Alexander and S.E. Leeman,
University of Massachusetts Medical Center, Boston, MA

ANTIPSYCHOTIC DRUG INDUCED ALTERATION IN NEUROTENSIN CONCENTRATION: PRECLINICAL AND CLINICAL ASPECTS
C. Nemeroff, Duke University, Durham, NC

NEUROTENSIN-DOPAMINE RELATIONSHIPS WITHIN THE TUBEROINFUNDIBULAR NEURONS
G. A. Gudelsky and S.A. Berry, Case Western Reserve University, Cleveland, OH

SELECTIVE ANTAGONISM OF DOPAMINE $D_2$ RECEPTOR TRANSDUCTION IN THE BASAL GANGLIA BY NEUROTENSIN RECEPTOR ACTIVATION
K. Füxe, G. Von Euler, S. Tanganelli, W.T. O'Connor, F. Benfenati*, E. Merlo Pich*, A. Biagini* and L.F. Agnati*. Karolinska Institute, Stockholm, Sweden.
*University of Modena, Italy

NEUROTENSIN AND DA RELEASE IN THE RAT MEDIAL PREFRONTAL CORTEX *IN VIVO:* PHARMACOLOGICAL AND PHYSIOLOGICAL STUDIES
R.H. Roth and A.J. Bean. Yale University School of Medicine, New Haven, CT

## *Recent Advances in Neuropeptide Catabolism*

**Chair: A. Lajtha, Orangeburg, New York, USA**

AMINOPEPTIDASE HETEROGENEITY
A. Lajtha, Nathan Kline Research Inst. Orangeburg, NY

METALLOPEPTIDASE: MOLECULAR CHARACTERIZATION AND DEVELOPMENT OF INHIBITORS FOR THERAPEUTIC USE
J.C. Schwartz, Neurobiologie et pharmacologie, INSERM, Paris, France

ELUCIDATION OF THE ACTIVE SITE OF NEUTRAL ENDOPEPTIDASE (ENKEPHALINASE) BY SITE-DIRECTED MUTAGENASIS
L. Hersh and B. Shriver, University of Texas, Southwestern Med. Center, Dallas, TX

NEUROPEPTIDE PROCESSING MECHANISMS
P. Cohen, University Pierre et Marie Curie, INSERM, Paris, France

PITUITARY ENDOPEPTIDASES IN THE PROCESSING OF PRO-OPIOMELANOCORTIN
Y. Peng Loh, NICHND/NIH, Bethesda, MD

## *Neuropeptides and Growth Factors*

**Chair: L. Villa-Komaroff, Boston, Massachusetts, USA**

INTRODUCTION AND OVERVIEW
L. Villa-Komaroff, The Childrens Hospital, Boston, MA

THE SIGNIFICANCE OF PEPTIDE-PRODUCING NEURONS IN THE IMMATURE BRAIN
J. Chun, Whitehead Inst., MA

THE ROLE OF TRANSMITTERS IN BRAIN DEVELOPMENT
M.P. Mattson, Univ. of Kentucky, KY

VIP AS A TROPHIC FACTOR FOR CULTURED NEURONS
E.M. DiCiccio-Bloom, Robert Wood Johnson Med. School, NJ

THE ROLE OF SOMATOSTATIN IN THE DEVELOPING RETINA
D.M. Ferriero, Univ. California San Francisco, CA

Source: https://www.industrydocuments.ucsf.edu/docs/rgnv0000

## *Neural and Endothelial Peptides*

***Chair: G. Terenghi, London, UK***

NEURAL AND ENDOTHELIAL FACTORS IN THE DISEASE OF THE SKIN
P.M. Dowd (London)

NEUROPEPTIDE RECEPTOR HETEROGENEITY
R. Quirion (Canada)

NEUROPEPTIDES IN CARDIOVASCULAR DISEASES
J.M. Lundberg (Sweden)

ROLE OF CGRP AND ENDOTHELIN IN THE CONTROL OF PERIPHERAL BLOOD FLOW
S.D. Brain (London)

NEUROPEPTIDES AND ENDOTHELIN IN PERIPHERAL NEUROPATHIES
G. Terenghi (London)

## *Neuropeptides in the Lung*

**Co-Chairs: S. Said and J. Taylor**
**Stony Brook, NY. and Hopkinton, MA, USA**

NEUROPEPTIDES AND CELL PROLIFERATION IN THE LUNG
John E. Taylor, Hopkinton, MA

NEUROPEPTIDES AND SMALL-CELL LUNG CANCER
Terry W. Moody, Washington, DC

THE VIP RECEPTOR IN THE LUNG
Gonul Velicelebi, La Jolla, CA

SENSORY NEUROPEPTIDES IN THE LUNG
Bradley J. Undem, Baltimore, MD

VIP AND RELATED PEPTIDES AS ANTI-INFLAMMATORY AGENTS
Sami I. Said, Stony Brook, NY

## *Functional Role of Amine-Peptide Interactions: Emphasis on Cholecystokinin and Dopamine*

**Co-Chairs: R. Murphy and L. Schneider**
**New York University and Cornell University, New York, USA**

INTRODUCTORY REMARKS
R.M. Murphy, New York Univ., NY, NY

ELECTROPHYSIOLOGICAL EVIDENCE FOR CCK-DOPAMINE INTERACTIONS: RELEVANCE TO PHYSIOLOGICAL REGULATION OF DOPAMINE NEURONS
A. Freeman, Sinai Hospital, Detroit, MI

EVIDENCE FOR THE EXISTENCE OF CCK/DOPAMINE RECEPTORS IN THE BASAL GANGLIA
K. Füxe, Karolinska Inst. Stockholm, Sweden

CHOLECYSTOKININ RECEPTOR SUBTYPES IN CCK POTENTIATION OF DA-MEDIATED EXPLORATORY LOCOMOTION
J. Crawley, NIMH, Bethesda, MD

CCK: SUBSTRATES MEDIATING POTENTIATION AND ATTENUATION OF DA MEDIATED BEHAVIOR
F.J. Vaccarino, Univ. of Toronto, Canada

PEPTIDE INTERACTIONS WITH THE REINFORCING EFFECTS OF DA IN THE NUCLEUS ACCUMBENS
G. Koob, Scripps Clinic, La Jolla, CA

## *How Functionally Important are Endogenous Neuropeptides?*

**Chair: J. Crawley, Bethesda, MD, USA**

INTRODUCTION: WHICH CAME FIRST, THE PEPTIDE OR THE "CLASSICAL" NEUROTRANSMITTER?
J. Crawley, NIMH, Bethesda, MD

ARE PEPTIDES RELEASED UNDER PHYSIOLOGICAL CONDITIONS?
A.J. Bean. Karolinska Institutet, Stockholm, Sweden

MIGHT NEUROPEPTIDES FUNCTION PRIMARILY AS GROWTH FACTORS DURING NERVE DEVELOPMENT AND REGENERATION?
F.L. Strand, New York University, New York, NY

DO PEPTIDE RECEPTOR ANTAGONISTS PRODUCE BEHAVIORAL EFFECTS?
G.F. Koob. Scripps Clinic, La Jolla, CA

Source: https://www.industrydocuments.ucsf.edu/docs/rgnv0000